Table 1:

Participant characteristics

	Characteristic, No. of participants in follow-up cohort (%)*		No. of participants in vaccine-naive cohort (%)*
	Group 1 n = 100	Group 2 n = 11	Group 3 n = 12	Group 4 n = 209
Ages at previously administered 4CMenB doses, mo	12, 14	18, 20	24, 26	NA
No. of doses administered	1	1	1	2 (2 mo apart)
Age at administration of first dose, mo; mean ± SD	51.7 ± 3.3	53.4 ± 4.3	56.8 ± 1.5	53.7 ± 3.6
Male sex (%)	50 (50.0)	5 (45)	8 (67)	110 (53)
White (%)	97 (97.0)	8 (73)	7 (58)	193 (92)
Weight, kg; mean ± SD	18.1 ± 2.4†	18.7 ± 2.4‡	18.8 ± 1.8§	18.1 ± 2.5¶
Height, cm; mean ± SD	106 ± 4	107 ± 4	108 ± 6	107 ± 5**

Note: 4CMenB = capsular group B meningococcal vaccine, hSBA = human serum bactericidal antibody, NA = not applicable, SD = standard deviation. All participants in the follow-up cohort received 2 previous doses of 4CMenB vaccine at 12 and 14 mo (Group 1), 18 and 20 mo (Group 2) or 24 and 26 mo (Group 3) in a previous study.²¹ Group 4 included participants with no previous 4CMenB vaccination.

^*Unless specified otherwise.

^†Denominator used: n = 91.

^‡Denominator used: n = 9.

^§Denominator used: n = 11.

^¶Denominator used: n = 189.

^**Denominator used: n = 205.